Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Mesothelioma treatment delays that happened because of the COVID-19 pandemic will probably impact survival rates for some patients. A new study of Canadian lung cancer patients found that more than half of them stopped or delayed treatment because of concerns about the virus this spring. Pleural mesothelioma is a lung-related cancer. Like lung cancer patients, mesothelioma patients face a higher risk of virus-related complications because they already have breathing problems. But mesothelioma is also a fast-growing cancer. Most patients get several kinds of treatment at the same time. Mesothelioma treatment delays may give tumors a chance to grow unchecked. A Catch-22 for Mesothelioma Patients Mesothelioma patients and others with lung diseases have had to make some difficult decisions because of … Continue reading Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Gene Targeting Slows Aggressive Form of Pleural Mesothelioma
Scientists in Vienna are developing a new treatment for a particularly aggressive form of pleural mesothelioma. This form of mesothelioma occurs in people with a genetic mutation. The mutation produces signals that fuel tumor growth. These patients typically have an even worse prognosis than other mesothelioma patients. But the Austrian team came up with a way to block activation of the mutated gene. If the gene does not send its signal, this aggressive form of pleural mesothelioma may grow more slowly. Aggression Fueled by Telomerase Malignant mesothelioma is one of the most aggressive kinds of cancer. It starts on the membranes around organs and can quickly spread to other parts of the body. By the time most people notice symptoms, … Continue reading Gene Targeting Slows Aggressive Form of Pleural Mesothelioma
The Peritoneal Cancer Index in Mesothelioma Prognosis
The peritoneal cancer index is a valuable prognostic tool and should be considered in mesothelioma treatment planning. That is the word from a group of Finnish cancer researchers. They analyzed twelve years of data on peritoneal mesothelioma in their country. Mesothelioma patients with a higher peritoneal cancer index had a worse prognosis than those with a lower PCI. The group says cancer doctors ought to be including the PCI in their decision-making for people with peritoneal mesothelioma. What is the Peritoneal Cancer Index? Peritoneal mesothelioma makes up about a fifth of all mesothelioma cases. It grows on the peritoneum, a membrane that surrounds the abdominal organs. As cancer spreads, tumors can show up in other areas inside the peritoneal cavity. … Continue reading The Peritoneal Cancer Index in Mesothelioma Prognosis
Breath Test for Mesothelioma Might Identify Subtypes
Researchers in the UK say a breath test for mesothelioma might be able to distinguish between mesothelioma subtypes. There are three major subtypes of mesothelioma. It is important to know which kind of person has. A patient’s subtype can impact their prognosis and even their mesothelioma treatment choice. Right now, the only way to tell the mesothelioma subtypes apart is to look at the cells under the microscope. But scientists at Sheffield Hallam University have identified volatile organic compounds (VOCs) in the rarest and the most common mesothelioma subtypes. These VOCs could be used to develop a mesothelioma breath test that could tell the subtypes apart. The Advantages of Breath Testing Breath testing is a way of measuring VOCs in … Continue reading Breath Test for Mesothelioma Might Identify Subtypes
The Best Biomarkers for Mesothelioma Diagnosis, Prognosis, & Monitoring
What are the best biomarkers for mesothelioma? The answer is still Soluble Mesothelin-Related Proteins (SMRPs). That is the conclusion of a major review of medical literature by some of the world’s top mesothelioma experts. Dr. Harvey Pass of New York University’s Langone Medical Center and Dr. Michele Carbone of the University of Hawaii are among the authors on the new report. They analyzed 20 years of research on the best biomarkers for mesothelioma. Several were valuable for mesothelioma prognosis. But SMRPs once again came out the winner for mesothelioma prognosis, diagnosis, and treatment monitoring. How Do Biomarkers Work? A biomarker is any substance produced by the body that can act as a biological signpost. Proteins usually make the best biomarkers … Continue reading The Best Biomarkers for Mesothelioma Diagnosis, Prognosis, & Monitoring
Predicting Mesothelioma Outcomes with FDG-PET: A New Model
Swiss doctors have created a new tool for predicting mesothelioma outcomes with FDG-PET scans. FDG-PET scanning is a nuclear imaging technique. It gives doctors a non-invasive way to track the growth of pleural mesothelioma tumors. The Swiss team analyzed multiple PET scans and CT scans from mesothelioma patients. They used a computer to look for commonalities in the scans. Then they used the information to create a computer model for predicting mesothelioma outcomes with FDG-PET. The model may help doctors and patients make better decisions about mesothelioma treatment in the future. Imaging Studies for Mesothelioma Prognosis Pleural mesothelioma tumors occur on the pleural lining around the lungs. In the early stages, mesothelioma causes few symptoms. As mesothelioma tumors grow, they … Continue reading Predicting Mesothelioma Outcomes with FDG-PET: A New Model
Some Long-Term Mesothelioma Survivors May Have Few Symptoms
New research shows that some long-term mesothelioma survivors may have few or no symptoms of the disease for years. The research appears in a recent issue of the journal Clinical Lung Cancer. A team of Finnish doctors wanted to identify the unique characteristics of long-term mesothelioma survivors. They discovered that some of these survivors seem to have an indolent form of asbestos cancer. This suggests that it is possible for a person to live for many years with pleural mesothelioma and not even know they have it. Typical Mesothelioma Symptoms It is not unusual for mesothelioma patients to have no symptoms in the early stages, but long-term mesothelioma survivors are rare. Once the cancer takes hold, it usually grows quickly. … Continue reading Some Long-Term Mesothelioma Survivors May Have Few Symptoms
BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis
A new report says the prognostic role of BAP1 expression in mesothelioma is not as cut-and-dried as some studies suggest. Italian researchers analyzed the cases of 698 patients with pleural mesothelioma. The group included 60 of their own patients and another 638 from other studies. Their analysis suggests that mesothelioma prognosis has more to do with subtype than with genetic BAP1 expression. They caution doctors not to put too much stock in a patient’s BAP1 status without also considering other factors. Genetic Alterations and Mesothelioma Survival Asbestos exposure is the primary cause of mesothelioma. But not everyone who is exposed to asbestos gets cancer. This may have to do with their genetic makeup. Certain genetic alterations may make a person … Continue reading BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis
Predicting the Risk of Death from Mesothelioma
New research suggests that the risk of death from mesothelioma does not always hinge on disease type or overall health. Researchers in Brazil and at Mayo Clinic have identified some subtle mesothelioma risk factors that only pathologists can see. These factors go beyond the characteristics of the mesothelioma cells themselves. The study shows the environment around the tumor, the number and type of immune system cells at the tumor site, and even how many cells are in the tumor can all impact the risk of death from mesothelioma. Understanding the Risk Factors for Mesothelioma Asbestos exposure causes most cases of mesothelioma. But not everyone who encounters asbestos gets cancer. Genes and certain lifestyle factors may influence whether an exposed person … Continue reading Predicting the Risk of Death from Mesothelioma
PD-L1 Expression and Mesothelioma Prognosis
The largest study yet on PD-L1 expression and mesothelioma prognosis shows that patients with more of this protein in their cells have poorer odds of survival. Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack. Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But the new meta-analysis performed by two Chinese researchers appears to confirm it with an even bigger data set. Understanding Mesothelioma Prognosis Malignant mesothelioma is an uncommon cancer that typically carries a poor prognosis. Many people diagnosed with mesothelioma lose their lives to the illness within a year. But there are also many exceptions. Some mesothelioma survivors live for decades after a mesothelioma diagnosis. Australian Paul Kraus is an example. … Continue reading PD-L1 Expression and Mesothelioma Prognosis
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!